Spots Global Cancer Trial Database for neuroendocrine carcinoma
Every month we try and update this database with for neuroendocrine carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| 5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors | NCT00953394 | Neuroendocrine ... | continuous 5 fl... | 18 Years - | University of Turin, Italy | |
| Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer | NCT01642251 | Extensive Stage... Large Cell Lung... Neuroendocrine ... Small Cell Carc... Stage IV Non-Sm... | Cisplatin Etoposide Veliparib Placebo | 18 Years - | National Cancer Institute (NCI) | |
| Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma | NCT03837977 | Oncology Neuroendocrine ... | Liposomal Irino... Fluorouracil Folinic Acid Docetaxel | 18 Years - | The Christie NHS Foundation Trust | |
| An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours | NCT02236910 | Neuroendocrine ... | Lu-DOTA-TATE | 14 Years - 90 Years | Lawson Health Research Institute | |
| A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors | NCT03517488 | Melanoma Breast Carcinom... Hepatocellular ... Urothelial Carc... Squamous Cell C... Renal Cell Carc... Colorectal Carc... Non-small Cell ... Gastric or Gast... Endometrial Car... Mesothelioma Neuroendocrine ... Cervical Cancer Small Cell Lung... Squamous Cell C... Castration-Resi... Nasopharyngeal ... Cholangiocarcin... Basal Cell Carc... Ovarian Carcino... Fallopian Tube ... Thymoma Thymic Carcinom... Squamous Cell C... Vulvar Carcinom... Solid Tumors Wi... Malignant Adnex... Non-squamous Ce... | XmAb20717 | 18 Years - | Xencor, Inc. | |
| 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors | NCT02038738 | Neuroendocrine Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Carcinoid Carcinoid Tumor Islet Cell Tumo... Apudoma | 68Ga-DOTATATE w... | 18 Years - | Ochsner Health System | |
| Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms | NCT05709171 | GEP-NET Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... | 18F-FDG 64Cu-Dotatate | 18 Years - | Rigshospitalet, Denmark | |
| 68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors | NCT02038738 | Neuroendocrine Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Carcinoid Carcinoid Tumor Islet Cell Tumo... Apudoma | 68Ga-DOTATATE w... | 18 Years - | Ochsner Health System | |
| Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer | NCT03110978 | Lung Atypical C... Lung Neuroendoc... Lung Non-Small ... Minimally Invas... Neuroendocrine ... Recurrent Lung ... Recurrent Lung ... Recurrent Lung ... Stage I Lung Ca... Stage IA1 Lung ... Stage IA2 Lung ... Stage IA3 Lung ... Stage IB Lung C... Stage IIA Lung ... | Nivolumab Stereotactic Bo... | 18 Years - | M.D. Anderson Cancer Center | |
| Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma | NCT03901378 | Neuroendocrine ... Large Cell Neur... High Grade Neur... | Pembrolizumab | 18 Years - | Ochsner Health System | |
| Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma | NCT00663429 | Neuroendocrine ... | Atiprimod | 18 Years - | Callisto Pharmaceuticals | |
| TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors | NCT03079440 | Neuroendocrine ... Neuroendocrine ... Temozolomide Capecitabine | TEMCAP | 19 Years - | Asan Medical Center | |
| Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors | NCT00004922 | Carcinoma of Un... Neuroendocrine ... Neuroendocrine ... | irinotecan hydr... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract | NCT04069299 | Neuroendocrine ... | 68Ga-DOTATATE Positron Emissi... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma | NCT00193531 | Neuroendocrine ... | Paclitaxel Carboplatin Etoposide | 18 Years - | SCRI Development Innovations, LLC | |
| Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma | NCT03168607 | Neuroendocrine ... | FOLFIRI Protoco... | 18 Years - | Peking University | |
| A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma. | NCT05747729 | Neuroendocrine ... | Surufatinib and... | 18 Years - | Wuhan Union Hospital, China | |
| Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After Chemotherapy | NCT03352934 | Cancer | Avelumab | 18 Years - | Johannes Gutenberg University Mainz | |
| Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers | NCT01121939 | Neuroendocrine ... | Bevacizumab Pertuzumab Sandostatin LAR... | 18 Years - | SCRI Development Innovations, LLC | |
| A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma. | NCT05747729 | Neuroendocrine ... | Surufatinib and... | 18 Years - | Wuhan Union Hospital, China | |
| Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary | NCT04325425 | Neuroendocrine ... | FOLFOXIRI Proto... Cisplatin injec... | 18 Years - | Centre Hospitalier Universitaire Dijon | |
| Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma | NCT00388063 | Neuroendocrine ... | Atiprimod | 18 Years - | Callisto Pharmaceuticals | |
| RegisterNET - A Registry for Neuroendocrine Tumors in the USA | NCT02270567 | Neuroendocrine ... Carcinoid Neuroendocrine ... | NETest | 21 Years - | Wren Laboratories LLC | |
| Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy | NCT00363051 | Islet Cell Carc... Neuroendocrine ... Neuroendocrine ... Pancreatic Neop... | Everolimus 10 m... Octreotide Depo... | 18 Years - | Novartis | |
| Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer | NCT03728361 | Grade I Neuroen... Grade II Neuroe... Grade III Neuro... Metastatic Neur... Neuroendocrine ... Recurrent Small... Refractory Smal... Lung Cancer Sta... Large Cell Neur... Neuroendocrine ... Small Cell Lung... Small-cell Lung... | Nivolumab Temozolomide | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Neuroendocrine Tumors - Patient Reported Outcomes | NCT05064150 | Neuroendocrine ... Gastroenteropan... Lung Neuroendoc... Neuroendocrine ... | 18 Years - | University of Iowa | ||
| PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers | NCT02936323 | Neuroendocrine ... Carcinoma, Smal... Neuroendocrine ... | PEN-221 PEN-221 | 18 Years - | Tarveda Therapeutics | |
| Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers | NCT01121939 | Neuroendocrine ... | Bevacizumab Pertuzumab Sandostatin LAR... | 18 Years - | SCRI Development Innovations, LLC | |
| TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors | NCT03079440 | Neuroendocrine ... Neuroendocrine ... Temozolomide Capecitabine | TEMCAP | 19 Years - | Asan Medical Center | |
| Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery | NCT02315625 | Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Carcinoma, Neur... Neuroendocrine ... | Sunitinib Everolimus | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Lung Cancer STARS Trial - STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy | NCT02357992 | Lung Cancer | Stereotactic Bo... | 18 Years - | M.D. Anderson Cancer Center | |
| Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors | NCT00004922 | Carcinoma of Un... Neuroendocrine ... Neuroendocrine ... | irinotecan hydr... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine Neoplasms | NCT03834701 | Neuroendocrine ... Neuroendocrine ... Pancreas Neopla... Neuroendocrine ... | EUS guided radi... | 18 Years - 80 Years | Catholic University of the Sacred Heart | |
| Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN) | NCT04464122 | Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... | Somatostatin an... | 18 Years - 80 Years | University of Roma La Sapienza | |
| The Molecular Screening Study for the Umbrella Trial (SUKSES) in Relapsed Small Cell Lung Cancer Patients [SUKSES-S] | NCT02688894 | Small Cell Lung... Neuroendocrine ... | No treatment is... | 20 Years - | Samsung Medical Center | |
| Avelumab in G3 NEC | NCT03278405 | Neuroendocrine ... | Avelumab | 18 Years - | Sunnybrook Health Sciences Centre | |
| RegisterNET - A Registry for Neuroendocrine Tumors in the USA | NCT02270567 | Neuroendocrine ... Carcinoid Neuroendocrine ... | NETest | 21 Years - | Wren Laboratories LLC | |
| RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma | NCT00113360 | Neuroendocrine ... Islet Cell Carc... | RAD001 Octreotide Depo... | 18 Years - | M.D. Anderson Cancer Center | |
| Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | NCT03074513 | Appendix Adenoc... Human Papilloma... Human Papilloma... Human Papilloma... Human Papilloma... Neuroendocrine ... Pancreatic Neur... Recurrent Merke... Recurrent Nasop... Recurrent Perit... Recurrent Pleur... Stage III Merke... Stage III Nasop... Stage III Pleur... Stage IV Merkel... Stage IV Nasoph... Stage IV Pleura... Stage IVA Nasop... Stage IVB Nasop... Stage IVC Nasop... Vaginal Squamou... | Atezolizumab Bevacizumab Laboratory Biom... Pharmacological... | 18 Years - | M.D. Anderson Cancer Center | |
| Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET | NCT05420636 | Small-cell Lung... Neuroendocrine ... | Iadademstat Paclitaxel | 18 Years - | Fox Chase Cancer Center | |
| Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas | NCT04268121 | Neuroendocrine ... Digestive Cance... | Neoadjuvant tre... Adjuvant treatm... | 18 Years - | GERCOR - Multidisciplinary Oncology Cooperative Group | |
| Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3) | NCT02248012 | Neuroendocrine ... | Everolimus , te... | 18 Years - | Haukeland University Hospital | |
| A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas | NCT05619744 | Small Cell Lung... Neuroendocrine ... | RO7616789 Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma. | NCT06372626 | Neuroendocrine ... | ZG005 Etoposide Cisplatin Placebo | 18 Years - 70 Years | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | |
| Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma | NCT00388063 | Neuroendocrine ... | Atiprimod | 18 Years - | Callisto Pharmaceuticals | |
| Study to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With Cisplatin (EP) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Carcinoma | NCT03168594 | Neuroendocrine ... | irinotecan cisp... Etoposide cispl... | 18 Years - | Peking University | |
| Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma | NCT00388063 | Neuroendocrine ... | Atiprimod | 18 Years - | Callisto Pharmaceuticals | |
| 68Ga-DOTATATE PET Scan in Neuroendocrine Cancer | NCT01396382 | Neuroendocrine ... | 68Ga-DOTATATE P... | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas | NCT04701307 | Lung Small Cell... Neuroendocrine ... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... | Dostarlimab Niraparib | 18 Years - | M.D. Anderson Cancer Center | |
| Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma | NCT00663429 | Neuroendocrine ... | Atiprimod | 18 Years - | Callisto Pharmaceuticals | |
| TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors | NCT03079440 | Neuroendocrine ... Neuroendocrine ... Temozolomide Capecitabine | TEMCAP | 19 Years - | Asan Medical Center | |
| Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine Neoplasms | NCT03834701 | Neuroendocrine ... Neuroendocrine ... Pancreas Neopla... Neuroendocrine ... | EUS guided radi... | 18 Years - 80 Years | Catholic University of the Sacred Heart | |
| Safety and Efficacy of FOLFSIM Plus Toripalimab in the Treatment of Advanced or Metastatic Neuroendocrine Carcinoma | NCT03992911 | Neuroendocrine ... | Simmtecan, 5-FU... Toripalimab Etoposide, Cisp... Etoposide, Carb... | 18 Years - 75 Years | Peking University | |
| Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC | NCT06369181 | Neuroendocrine ... Non-small Cell ... Histology Trans... | 18 Years - | Fudan University | ||
| Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine Neoplasms | NCT03834701 | Neuroendocrine ... Neuroendocrine ... Pancreas Neopla... Neuroendocrine ... | EUS guided radi... | 18 Years - 80 Years | Catholic University of the Sacred Heart | |
| Investigation of 68Ga-DOTATATE, as a PET Imaging Agent in Neuroendocrine Tumor Patients | NCT01873248 | Neuroendocrine ... | 68Ga-DOTATATE | 18 Years - | Jonsson Comprehensive Cancer Center | |
| CAPTEM or FOLFIRI as SEcond-line Therapy in NEuroendocrine CArcinomas | NCT03387592 | Neuroendocrine ... | CPT-11 Calcio levofoli... 5-Fluorouracil Capecitabine Temozolomide | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| Phase I Trial: 68Ga-NODAGA-E(c[RGDyK])2 Positron Emission Tomography for Imaging Angiogenesis in Primary and Metastatic Tumor Lesions in Humans | NCT02970786 | Neuroendocrine ... Breast Cancer Ovarian Cancer | Injection of 68... | 50 Years - 85 Years | Rigshospitalet, Denmark | |
| Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary | NCT04325425 | Neuroendocrine ... | FOLFOXIRI Proto... Cisplatin injec... | 18 Years - | Centre Hospitalier Universitaire Dijon | |
| Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | NCT03074513 | Appendix Adenoc... Human Papilloma... Human Papilloma... Human Papilloma... Human Papilloma... Neuroendocrine ... Pancreatic Neur... Recurrent Merke... Recurrent Nasop... Recurrent Perit... Recurrent Pleur... Stage III Merke... Stage III Nasop... Stage III Pleur... Stage IV Merkel... Stage IV Nasoph... Stage IV Pleura... Stage IVA Nasop... Stage IVB Nasop... Stage IVC Nasop... Vaginal Squamou... | Atezolizumab Bevacizumab Laboratory Biom... Pharmacological... | 18 Years - | M.D. Anderson Cancer Center | |
| PrognostIc and Predictive Factors in Unresectable Locally Advanced NEC and MANEC | NCT06400654 | Neuroendocrine ... | 18 Years - | European Institute of Oncology | ||
| Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET | NCT05420636 | Small-cell Lung... Neuroendocrine ... | Iadademstat Paclitaxel | 18 Years - | Fox Chase Cancer Center | |
| Phase I Trial: 68Ga-NODAGA-E(c[RGDyK])2 Positron Emission Tomography for Imaging Angiogenesis in Primary and Metastatic Tumor Lesions in Humans | NCT02970786 | Neuroendocrine ... Breast Cancer Ovarian Cancer | Injection of 68... | 50 Years - 85 Years | Rigshospitalet, Denmark | |
| Study in Patients With Advanced Cancers Associated With Expression of DLL3 | NCT04471727 | Small-Cell Lung... Neuroendocrine ... | HPN328 Atezolizumab | 18 Years - 100 Years | Harpoon Therapeutics | |
| A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas | NCT05619744 | Small Cell Lung... Neuroendocrine ... | RO7616789 Tocilizumab | 18 Years - | Hoffmann-La Roche | |
| Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After Chemotherapy | NCT03352934 | Cancer | Avelumab | 18 Years - | Johannes Gutenberg University Mainz | |
| Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN) | NCT04464122 | Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... | Somatostatin an... | 18 Years - 80 Years | University of Roma La Sapienza | |
| The Aim of This Study is to Demonstrat That Vacuum-assisted Closure Versus Conventional Wound Closure Enables to Diminish Local Complications After Lymph Node Dissection in Patients With Metastatic Skin Tumors | NCT04583605 | Melanoma Skin Cancer Epidermoid Carc... Neuroendocrine ... Lymph Node Meta... | PREVENA | 18 Years - | Central Hospital, Nancy, France | |
| Neuroendocrine Tumors - Patient Reported Outcomes | NCT05064150 | Neuroendocrine ... Gastroenteropan... Lung Neuroendoc... Neuroendocrine ... | 18 Years - | University of Iowa | ||
| Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors | NCT03290079 | Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... | Pembrolizumab Lenvatinib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma. | NCT06440057 | Neuroendocrine ... | ZG006 | 18 Years - 75 Years | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | |
| Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) | NCT03591731 | Neuroendocrine ... | Nivolumab Ipilimumab | 18 Years - | Intergroupe Francophone de Cancerologie Thoracique | |
| Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy | NCT05627427 | Neuroendocrine ... Neuroendocrine ... Pancreatic Carc... | Surufatinib Sintilimab | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| RegisterNET - A Registry for Neuroendocrine Tumors in the USA | NCT02270567 | Neuroendocrine ... Carcinoid Neuroendocrine ... | NETest | 21 Years - | Wren Laboratories LLC | |
| A Trial of Cabozantinib in Patients With Advanced, Low Proliferative NEN G3 | NCT04524208 | Neuroendocrine ... Neuroendocrine ... | Cabozantinib | 18 Years - | University Medical Center Goettingen | |
| 68-Ga-DOTATATE PET-CT Scan for Diagnosis of Primary and Metastatic Somatostatin Receptor-positive Neuroendocrine Tumors (NETs) | NCT01879657 | Neuroendocrine ... | 68Ga-DOTATATE i... | 18 Years - | Radio Isotope Therapy of America | |
| A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma. | NCT05747729 | Neuroendocrine ... | Surufatinib and... | 18 Years - | Wuhan Union Hospital, China | |
| Study in Patients With Advanced Cancers Associated With Expression of DLL3 | NCT04471727 | Small-Cell Lung... Neuroendocrine ... | HPN328 Atezolizumab | 18 Years - 100 Years | Harpoon Therapeutics | |
| Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery | NCT02315625 | Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Carcinoma, Neur... Neuroendocrine ... | Sunitinib Everolimus | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary | NCT04325425 | Neuroendocrine ... | FOLFOXIRI Proto... Cisplatin injec... | 18 Years - | Centre Hospitalier Universitaire Dijon |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
